Covington & Burling advised OrbiMed on the deal.OrbiMed announced its $125 million debt financing with Verrica Pharmaceuticals, a dermatology therapeutics company developing medications for skin diseases requiring…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
